206 results about "Controlled substance" patented technology

The present invention provides improved devices and methods for inhibiting restenosis and hyperplasia after intravascular intervention. In particular, the present invention provides luminal prostheses which allow for programmed and controlled substance delivery with increased efficacy to selected locations within a patient's vasculature to inhibit restenosis. The luminal delivery prosthesis comprises a scaffold which is implantable within a body lumen and means on the scaffold for releasing a substance from the scaffold. The substance is released over a predetermined time pattern comprising an initial phase wherein the substance delivery rate is below a threshold level and a subsequent phase wherein the substance delivery rate is above a threshold level.

A method of and system for identifying an individual drug delivery device and tracing its ownership. An individual drug delivery device, such as a patch, is coded with a unique identifier. Such coding is performed by using a bar code or by storing the identifier in a memory device in the drug delivery device. A database contains a record of the identifier, representing the drug delivery device. The identifier is read upon a transfer of the drug delivery device and the database is updated to include information such as the date of the transfer, the identity of the transferee and the prescribing physician. The ability to retrieve such information regarding specific drug delivery devices can result in the prevention of abuse of controlled substances contained therein.

A system is provided for delivery and monitoring the administration of controlled substances which includes one or more databases including a national database of controlled substance users, a database including physician/pharmacy information, a controlled substance delivery device and a docking station for use together with a network and software for communication between the various components of the system.

A plasmonic device has a plurality of nanostructures extending from a substrate. Each of the plurality of nanostructures preferably includes a core, a coating of intermediate material covering at least a portion of the core, and a coating of a plasmonic material. Devices are preferably manufactured using lithography to create the cores, and Plasma Enhanced Chemical Vapor Deposition (PECVD) to deposit the intermediate and/or plasmonic materials. Cores can be arranged in any suitable pattern, including one-dimensional or two-dimensional patterns. Devices can be used in airborne analyte detectors, in handheld roadside controlled substance detectors, in genome sequencing device, and in refraction detectors.

The present invention provides improved stents and other prostheses for delivering substances to vascular and other luminal and intracorporeal environments. In particular, the present invention provides luminal prostheses which allow for a programmed and controlled substance delivery protocols for a variety of purposes. The prostheses comprise a scaffold which is implantable within a body lumen and a substance reservoir present over at least a portion of the scaffold. Usually, a rate-controlling element will be formed over the substance-containing reservoir to provide for a number of different substance release characteristics.

A field deployable optical assembly for use in testing a light-responsive sample is disclosed. The assembly includes a microfluidic device, a first optical package, and a second optical package. The first optical package includes a light emitting diode (LED), a first optical device, and a first light-path control, the first optical package configured to guide and focus light from the LED onto the sample. The microfluidic device includes a tethered control substance. In response to a substance within the sample being associated with, and attaching to, the tethered control, the sample emits light. The second optical package includes a photo sensor, a second optical device, and a second light-path control, the second optical package configured to guide and focus the light emitted from the sample onto the photo sensor.

This invention discloses a nourishing slow-released type organic bulking agent for processing water and its preparation. This bulking agent includes 60-100 parts of high polymer basis material, 1-15 parts of nutrient substance, 1-10 parts of slow-releasing control substance, and 1-10 parts of dispersing lubricant. When prepare, lubricate slow-releasing control substance with 0.5-3 parts of dispersing lubricant; lubricate high polymer basis material with remaining dispersing lubricant, add in stirring machine, mix with above mixture, mix uniformly, transfer mixture into stirring dipper of plastic injection molding machine, extrude and form by bulking agent tooting. Organic bulking agent prepared by this invention slow-releases nutrient substance that is required for microbes forming biofilm. It has characteristics of fast forming biofilm, more microbial biomass, and activity. It is especially suitable for oxygen degrading process of waste water that contains difficult degraded toxic pollutant.

Disclosed is a vaporizer with a heating element located on a side opposite the mouthpiece. The heating element can heat an herbal product that is located away from the vaporizer and not within a canister that may require multiple heatings of the same product, producing a burnt flavor. The heating element can be in the shape of a coiled straw-like structure or otherwise incorporate a tubular passageway to provide better air flow during inhalation. The air flow tip and the tube can also be a single piece to allow for easier cleaning and replacement, or removal of the air flow tip if the tip includes resin of a controlled substance.

The present invention provides for devices and methods for vending regulated products, particularly controlled substances, including those containing pseudoephedrine. The present invention allows for the identification of consumers through reliable log-in-procedures, allows the consumer to select items, validates whether the purchase request complies with regulations, to facilitate the delivery of the requested product to a consumer. Other embodiments include a vending machine that is placed into a retail environment in which software enforces validation of the purchasers' identities, limits the amount of pseudoephedrine for each purchaser within the regulations of local, state and federal agencies.

This invention reduces the resources which must be expended in retail locations to comply with regulatory agencies, to implement effective counter measures against illegal purchases of regulated and controlled substances, and to ensure the effective limitation of these substances within reasonable limits required for normal consumption.

The invention relates generally to the field of substance and material detection, inspection, and classification at wavelengths between approximately 200 nm and approximately 1800 nm. In particular, a handheld Enhanced Photoemission Spectroscopy (“EPS”) detection system with a high degree of specificity and accuracy, capable of use at small and substantial standoff distances (e.g., greater than 12 inches) is utilized to identify specific substances (e.g., controlled substances, illegal drugs and explosives, and other substances of which trace detection would be of benefit) and mixtures thereof in order to provide information to officials for identification purposes and assists in determinations related to the legality, hazardous nature and/or disposition decision of such substance(s).

An activity monitor which can be pre-programmed at the factory, the doctors office or the pharmacist, or that can be programmed by the user. The activity monitor is affixed to a medicine bottle or container and activity associated with the bottle or container, such as movement, opening, volume changes, etc. are monitored in view to the schedule. The activity monitor records and allows for the analysis of the recorded data to determine is there is a likelihood of substance abuse.

An intelligent package system for holding or delivering medical pharmaceuticals, controlled substances, or hazardous materials includes at least one integral active display, a controller and one or more of the following: a programmable memory; one or more sensors; a communication interface device; a power source; one or more user input devices; and an externally connected device in communication with the controller/display. The active display allows static as well as dynamic visual information to be presented, and may be printed or stamped directly onto the surface of the pharmaceutical container or packaging to provide for enhanced information display, access, and visibility.

Techniques and devices for detecting and analyzing controlled substances and the like are discussed including highly reactive sensor molecules which are coated on a spectroscopic sample surface (4) and which may chemically react with a given analyte to form a covalently bonded adduct with spectral characteristics unique to the new adduct. The techniques provide the basis of a detection system with high sensitivity and high specificity in which the surface can even be washed to remove interfering or nonreactive compounds. The sensor molecules which comprise the coating (8) may have three major components: a central molecular scaffold ("CMS"), a "tether" terminated by a surface attachment group "SAG," and a reactive functional group "RFG" which may be highly reactive towards certain classes of molecules. One or more modifiers or modifier groups "Z" which may serve to increase or decrease the reactivity of the RFG towards target analytes, or to modify the spectral characteristics of the adduct may also be included. Some sensor molecules include diazonium compounds, activated acyls, and nitrosos.

A method, system, and apparatus for the collection, analysis, and disposal of controlled substances are described. A collector receives an excess of controlled substance and stores the controlled substance so that unauthorized access is minimized. An analysis determines the chemical composition and concentration. The results of the analysis are reviewed and reconciled against information in an overseeing authority information system or against information provided by the depositor of the controlled substance or both. The controlled substance is disposed of once it has been confirmed that the substance deposited in the collector is the same substance claimed to be deposited and the same substance issued by the pharmacy or other qualified authorities.

A container assembly has a material storage container defining a sealed chamber therein. A quantity of moisture-sensitive material is disposed in the chamber. The moisture-sensitive material has a desired range of moisture content. A hydrated humidity control substance is also disposed within the chamber, and the humidity control substance is in humidity-transferable communication with the chamber. The humidity control substance regulates a relative humidity within the chamber in order to maintain a moisture content of the moisture-sensitive material within the desired range of moisture content.

The invention provides a system and methods for centralized collection and verification of controlled substance/pharmaceutical waste. The invention provides a system and methods that replace the witness's co-signature with a process of centralized pharmacy controlled substance validation. In this process, the administering health care practitioner or nurse will give the medication to the patient and return the wasted portion of the dose to a secured storage area for a centralized pharmacy to pickup. The collected doses are then validated at the centralized pharmacy. Validation can include determining the composition, concentration, amount and type of drug.

A method, system, and apparatus for the collection, analysis, and disposal of controlled substances are described. A collector receives an excess of controlled substance and stores the controlled substance so that unauthorized access is minimized. An analysis determines the chemical composition and concentration. The results of the analysis are reviewed and reconciled against information in an overseeing authority information system or against information provided by the depositor of the controlled substance or both. The controlled substance is disposed of once it has been confirmed that the substance deposited in the collector is the same substance claimed to be deposited and the same substance issued by the pharmacy or other qualified authorities.

A secure dispensing device uses biofeedback to control release of a controlled substance. The secure dispensing device includes a housing with an access compartment that holds a controlled substance, the controlled substance including a first amount of the controlled substance to be dispensed according to one or more initial dispensation parameters; a controller that receives prescription bioinformation about a user and processes the prescription bioinformation to determine an adjusted dispensation parameter for the controlled substance to be dispensed, the initial dispensation parameter and the adjusted dispensation parameter of the controlled substance to be dispensed being different; a regulator that releases the controlled substance from within the housing; and an exit path with an opening that is sized for the controlled substance to be released outside of the access compartment.

The invention generally relates to compositions and methods with covalently bound compounds, such as controlled substances covalently attached to a chemical moiety, and opioid antagonists or covalently bound opioid antagonists to enhance analgesic potency and/or attenuate one or more adverse effects of covalently bound compounds, including adverse side effect(s) in humans such as nausea, vomiting, dizziness, headache, sedation (somnolence), physical dependence or pruritis. This invention relates to compositions and methods for selectively enhancing the analgesic potency of a covalently bound compound and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of a covalently bound compound. The methods of the invention comprise administering to a subject an analgesic or sub-analgesic amount of a covalently bound compound and an amount of excitatory opioid receptor antagonist such as naltrexone or nalmefene effective to enhance the analgesic potency of a covalently bound compound and attenuate the anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects of covalently bound compound. The invention also relates to the addition of covalently-bound opioid antagonists to the compositions containing covalently bound compounds such that if the compositions are subjected to manipulation by illicit chemists, the opioid antagonist is released effectively reducing or eliminating the euphoric effect of the covalently bound compounds.